Research programme: hepatitis B gene therapy - Janssen Sciences Ireland/University of the Witwatersrand

Drug Profile

Research programme: hepatitis B gene therapy - Janssen Sciences Ireland/University of the Witwatersrand

Alternative Names: Anti-HBV gene therapy - Janssen Sciences Ireland/University of the Witwatersrand; Anti-HBV TALENs - Janssen Sciences Ireland/University of the Witwatersrand

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator Janssen Sciences Ireland UC; University of the Witwatersrand
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 11 Jun 2015 The University of the Witwatersrand and Janssen Sciences Ireland UC agree to co-develop gene therapy in South Africa for Hepatitis B treatment
  • 11 Jun 2015 Early research in Hepatitis B treatment in South Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top